# Seasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy, clinical trial design and business development discussions.Strong industry reputation and commercial track record in high-value pharmaceutical markets including oncology and ophthalmology.

*biotech · news · 2026-04-22 · The Manila Times*

## Key points

- NovaBridge appointed Mark Hagler, ex-Sun Pharma CCO, as President and Chief Commercial Officer.
- Givastomig showed positive topline results in Phase 1b for first-line gastric cancer.
- VIS-101 completed a Phase 2a study for wet AMD and Phase 2b is planned for H2 2026.
- NovaBridge owns worldwide rights outside China to uliledlimab, targeting adenosine-driven immunosuppression in cancer.

**Companies:** NovaBridge Biosciences, Sun Pharmaceuticals Industries Limited, Ipsen S.A., Sanofi, Novartis AG, Abraxis BioScience, Inc.
**Countries:** United States

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/04/22/tmt-newswire/globenewswire/novabridge-appoints-mark-hagler-as-president-and-chief-commercial-officer-to-advance-commercial-strategy-and-maximize-pipeline-value/2325937)

---

Canonical: https://newsio.io/n/3d6ff982-ca02-434f-962d-5fe8a57c90e1/seasoned-biopharma-leader-bringing-deep-commercial-experience-to-shape-and-infor
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works